RainnieC personal page - To The Moon

RainnieC

RainnieC

No personal profile

11Follow

2Followers

0Topic

0Badge

2021-09-10

Hit the like button pls！?

Here's Why Ziopharm Oncology Stock Is Up 18% This Week

2021-09-10

Wow

4 of the Safest Dividend Stocks That'll Help You Crush Inflation

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4094332432138780,"uuid":"4094332432138780","gmtCreate":1631280410337,"gmtModify":1631288522149,"name":"RainnieC","pinyin":"rainniec","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cf3aed598fd853660a3a1e9ebe364fed","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":11,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":881037396,"gmtCreate":1631280951315,"gmtModify":1676530517583,"author":{"id":"4094332432138780","authorId":"4094332432138780","authorIdStr":"4094332432138780","name":"RainnieC","avatar":"https://static.tigerbbs.com/cf3aed598fd853660a3a1e9ebe364fed","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094332432138780"},"themes":[],"htmlText":"Hit the like button pls！?","listText":"Hit the like button pls！?","text":"Hit the like button pls！?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/881037396","repostId":"2166373377","repostType":4,"repost":{"id":"2166373377","pubTimestamp":1631280120,"share":"https://ttm.financial/m/news/2166373377?lang=&edition=fundamental","pubTime":"2021-09-10 21:22","market":"us","language":"en","title":"Here's Why Ziopharm Oncology Stock Is Up 18% This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2166373377","media":"Motley Fool","summary":"Recent insider stock purchases were more than a little encouraging.","content":"<h3>What happened</h3>\n<p>Shares of <b>Ziopharm Oncology</b> (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of insider stock purchases.</p>\n<h3>So what</h3>\n<p>Last Friday afternoon, just before Labor Day weekend, Ziopharm disclosed to the Securities and Exchange Commission four direct stock purchases from company insiders. James Huang, a financier of several lucrative life-science ventures including <b>Legend Biotech</b>, raised his stake from a little over 8,000 shares to around 108,000 shares. One of the company's largest shareholders, Robert Postma, bought 75,000 shares pushing his total Ziopharm holdings past 5.45 million shares.</p>\n<p><img src=\"https://static.tigerbbs.com/69f71c7423aa8bf2a971e693ce4d0936\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Kevin Boyle, who became CEO in August, wasn't <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the insiders who disclosed a big purchase on Sept. 3. That's probably because the company gave him 875,000 shares when he was appointed to the lead role on Aug. 30.</p>\n<h3>Now what</h3>\n<p>Insiders also happen to be people with bills to pay and luxuries to acquire. Investors need to remember that insider selling can mean lots of things that are mostly innocuous. Direct purchases like these, though, generally don't happen unless insiders expect the price to rise.</p>\n<p>At his former position as CEO of Kuur Therapeutics, Boyle led the company through a successful transformation that ended with a $185 million acquisition by <b>Athenex</b> this May.&nbsp;It looks like the board members who hired Boyle are confident about his ability to try Ziopharm around, too.</p>\n<p>The company's CD19-directed cellular therapy candidate started a trial in Taiwan this March, but it's on pause while the company refines its manufacturing process. With a clinical-stage pipeline collecting dust at the moment, Boyle has his work cut out for him.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ziopharm Oncology Stock Is Up 18% This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ziopharm Oncology Stock Is Up 18% This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Ziopharm Oncology (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166373377","content_text":"What happened\nShares of Ziopharm Oncology (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of insider stock purchases.\nSo what\nLast Friday afternoon, just before Labor Day weekend, Ziopharm disclosed to the Securities and Exchange Commission four direct stock purchases from company insiders. James Huang, a financier of several lucrative life-science ventures including Legend Biotech, raised his stake from a little over 8,000 shares to around 108,000 shares. One of the company's largest shareholders, Robert Postma, bought 75,000 shares pushing his total Ziopharm holdings past 5.45 million shares.\n\nImage source: Getty Images.\nKevin Boyle, who became CEO in August, wasn't one of the insiders who disclosed a big purchase on Sept. 3. That's probably because the company gave him 875,000 shares when he was appointed to the lead role on Aug. 30.\nNow what\nInsiders also happen to be people with bills to pay and luxuries to acquire. Investors need to remember that insider selling can mean lots of things that are mostly innocuous. Direct purchases like these, though, generally don't happen unless insiders expect the price to rise.\nAt his former position as CEO of Kuur Therapeutics, Boyle led the company through a successful transformation that ended with a $185 million acquisition by Athenex this May. It looks like the board members who hired Boyle are confident about his ability to try Ziopharm around, too.\nThe company's CD19-directed cellular therapy candidate started a trial in Taiwan this March, but it's on pause while the company refines its manufacturing process. With a clinical-stage pipeline collecting dust at the moment, Boyle has his work cut out for him.","news_type":1},"isVote":1,"tweetType":1,"viewCount":428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881033822,"gmtCreate":1631280609366,"gmtModify":1676530517427,"author":{"id":"4094332432138780","authorId":"4094332432138780","authorIdStr":"4094332432138780","name":"RainnieC","avatar":"https://static.tigerbbs.com/cf3aed598fd853660a3a1e9ebe364fed","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094332432138780"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881033822","repostId":"2166237337","repostType":4,"repost":{"id":"2166237337","pubTimestamp":1631280187,"share":"https://ttm.financial/m/news/2166237337?lang=&edition=fundamental","pubTime":"2021-09-10 21:23","market":"us","language":"en","title":"4 of the Safest Dividend Stocks That'll Help You Crush Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=2166237337","media":"Motley Fool","summary":"Inflation is high today, but don't get scared. These four dividend stocks have handily beat inflation over the long term.","content":"<p>Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own some dividend stocks with historically high levels of dividend growth. Here are four to consider today to help you win the prolonged war against inflation.</p>\n<h3>1. We gotta eat</h3>\n<p><b>Hormel Foods</b> (NYSE:HRL) owns well-regarded, often iconic, brands like SPAM, Skippy, Planters, and Wholly Guacamole. It is fiscally conservative and focuses on innovation. The food maker is expanding overseas and reaching into new distribution segments, augmenting its already strong position in the U.S. grocery and foodservice space. There is a lot to like about this company.</p>\n<p><img src=\"https://static.tigerbbs.com/06bccf8aa0aa78d1c0a7e773d5ea3f85\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<p>The stock's 2.3% dividend yield may not be huge, but is well above the miserly 1.3% on offer from the <b>S&amp;P 500</b> index. But the real magic is that Hormel has increased its dividend annually for 55 consecutive years. The average annualized hike over the past decade was a massive 15%. That's five times the 3% historical rate of inflation growth.</p>\n<p>The best part here, however, is that this Dividend King's yield is toward the high end of its historical range. That's partly due to the impact rising inflation will have on its business in the near term (which will probably slow near-term dividend growth some), but the company's long-term history suggests it will adjust and reward investors with strong dividend growth while it does.</p>\n<h3>2. Most people like it hot</h3>\n<p><b>A. O. Smith</b> (NYSE:AOS) makes hot water heaters, which is not a particularly sexy business unless you have to take a cold shower. Then you realize why the developing world, notably China and India, are such massive growth opportunities for the company. This is not a new trend or <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's likely to be short-term in nature. Basically, A. O. Smith has a growing business in areas where an expanding middle class all want the luxury of hot water on demand. And that, as it were, is backed by a solid and stable foundation in the North American market, where replacements of older systems is the driving force. It has been a potent mix for dividend investors.</p>\n<p>Like Hormel, A. O. Smith's dividend yield, at around 1.4%, is not giant. But its dividend growth has been nothing short of incredible, at an annualized 21% over the past decade. For reference, the industrial company is a Dividend Aristocrat with 28 years' worth of dividend increases under its belt. Simply put, the buying power of A. O. Smith's dividend has grown massively over time and easily kept investors ahead of inflation. Recent dividend hikes have been less impressive, to be fair, but they continue to outpace inflation by a sizable margin.</p>\n<h3>3. Not as mundane as it seems</h3>\n<p><b>NextEra Energy</b> (NYSE:NEE) might be a bit of a shock on this list, given that utilities are generally looked at as slow, safe, and boring. And that's a great description for the company's Florida Power &amp; Light business, which is one of the largest electric utility operations in the United States. Not only is it big -- this business has long benefited from the southward migration that's been taking place in the country. The thing is, that's just half of what NextEra does. The rest of the business is being a giant provider of renewable power, a high-growth sector that has helped to fuel this utility's dividend growth for many years.</p>\n<p><img src=\"https://media.ycharts.com/charts/2ca1f5068ba536739137e72323751cae.png\" tg-width=\"720\" tg-height=\"483\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>HRL Dividend Per Share (Quarterly) data by YCharts</p>\n<p>NextEra's dividend has increased at a 10% annualized clip over the past decade, a pace management believes is sustainable over the near term. That's huge growth for a utility. And, perhaps just as interesting, this is no flash-in-the-pan company, given its 27-year string of annual dividend increases. The stock's 1.8% yield is on the low side for a utility, but if you are trying to tame inflation with dividend growth stocks, NextEra is a strong option and could add valuable diversification to your portfolio.</p>\n<h3>4. A slow transition</h3>\n<p><b>Enbridge</b> (NYSE:ENB), the last name on this list, juxtaposes against NextEra, given that its core business is operating midstream energy assets that help move oil and natural gas around the world. The big picture here is important, however, because while clean energy is definitely growing in importance, it will likely be decades before carbon fuels are expunged from the global energy pie. So Enbridge's massive, virtually irreplaceable, and largely fee-based business likely has a long future ahead of it. In fact, the company continues to invest in its midstream operations even as it has started to build out its own renewables business, so it doesn't get left behind over the long term.</p>\n<p>But what's interesting here is that Enbridge has increased its dividend at a robust 10% clip over the past decade. Oh, and the fat 6.6% dividend yield thanks to the company's energy industry ties is pretty interesting, too. The dividend, for reference, has been increased annually for 26 consecutive years. The company also has material investment plans that should keep its dividend growing. The rate of growth, given the rising cost environment, may not match the historical rate, but it should still beat inflation. That makes this a great mix of yield and inflation protection.</p>\n<h3>You can fight inflation</h3>\n<p>Inflation, like most things in life, waxes and wanes over time. Right now inflation is top of mind because it is elevated, but it is something that dividend investors should always be thinking about. Growing the buying power of your dividends is a massive benefit that is far too often overlooked in a search for the biggest yields. Use today's inflation fears as a lesson that dividend growth rates stand toe to toe with yield in their importance and do a deep dive into Hormel, A. O. Smith, NextEra, and Enbridge today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 of the Safest Dividend Stocks That'll Help You Crush Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 of the Safest Dividend Stocks That'll Help You Crush Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HRL":"荷美尔","AOS":"A.O.史密斯","NEE":"新纪元能源","ENB":"安桥"},"source_url":"https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166237337","content_text":"Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own some dividend stocks with historically high levels of dividend growth. Here are four to consider today to help you win the prolonged war against inflation.\n1. We gotta eat\nHormel Foods (NYSE:HRL) owns well-regarded, often iconic, brands like SPAM, Skippy, Planters, and Wholly Guacamole. It is fiscally conservative and focuses on innovation. The food maker is expanding overseas and reaching into new distribution segments, augmenting its already strong position in the U.S. grocery and foodservice space. There is a lot to like about this company.\n\nImage source: Getty Images.\nThe stock's 2.3% dividend yield may not be huge, but is well above the miserly 1.3% on offer from the S&P 500 index. But the real magic is that Hormel has increased its dividend annually for 55 consecutive years. The average annualized hike over the past decade was a massive 15%. That's five times the 3% historical rate of inflation growth.\nThe best part here, however, is that this Dividend King's yield is toward the high end of its historical range. That's partly due to the impact rising inflation will have on its business in the near term (which will probably slow near-term dividend growth some), but the company's long-term history suggests it will adjust and reward investors with strong dividend growth while it does.\n2. Most people like it hot\nA. O. Smith (NYSE:AOS) makes hot water heaters, which is not a particularly sexy business unless you have to take a cold shower. Then you realize why the developing world, notably China and India, are such massive growth opportunities for the company. This is not a new trend or one that's likely to be short-term in nature. Basically, A. O. Smith has a growing business in areas where an expanding middle class all want the luxury of hot water on demand. And that, as it were, is backed by a solid and stable foundation in the North American market, where replacements of older systems is the driving force. It has been a potent mix for dividend investors.\nLike Hormel, A. O. Smith's dividend yield, at around 1.4%, is not giant. But its dividend growth has been nothing short of incredible, at an annualized 21% over the past decade. For reference, the industrial company is a Dividend Aristocrat with 28 years' worth of dividend increases under its belt. Simply put, the buying power of A. O. Smith's dividend has grown massively over time and easily kept investors ahead of inflation. Recent dividend hikes have been less impressive, to be fair, but they continue to outpace inflation by a sizable margin.\n3. Not as mundane as it seems\nNextEra Energy (NYSE:NEE) might be a bit of a shock on this list, given that utilities are generally looked at as slow, safe, and boring. And that's a great description for the company's Florida Power & Light business, which is one of the largest electric utility operations in the United States. Not only is it big -- this business has long benefited from the southward migration that's been taking place in the country. The thing is, that's just half of what NextEra does. The rest of the business is being a giant provider of renewable power, a high-growth sector that has helped to fuel this utility's dividend growth for many years.\n\nHRL Dividend Per Share (Quarterly) data by YCharts\nNextEra's dividend has increased at a 10% annualized clip over the past decade, a pace management believes is sustainable over the near term. That's huge growth for a utility. And, perhaps just as interesting, this is no flash-in-the-pan company, given its 27-year string of annual dividend increases. The stock's 1.8% yield is on the low side for a utility, but if you are trying to tame inflation with dividend growth stocks, NextEra is a strong option and could add valuable diversification to your portfolio.\n4. A slow transition\nEnbridge (NYSE:ENB), the last name on this list, juxtaposes against NextEra, given that its core business is operating midstream energy assets that help move oil and natural gas around the world. The big picture here is important, however, because while clean energy is definitely growing in importance, it will likely be decades before carbon fuels are expunged from the global energy pie. So Enbridge's massive, virtually irreplaceable, and largely fee-based business likely has a long future ahead of it. In fact, the company continues to invest in its midstream operations even as it has started to build out its own renewables business, so it doesn't get left behind over the long term.\nBut what's interesting here is that Enbridge has increased its dividend at a robust 10% clip over the past decade. Oh, and the fat 6.6% dividend yield thanks to the company's energy industry ties is pretty interesting, too. The dividend, for reference, has been increased annually for 26 consecutive years. The company also has material investment plans that should keep its dividend growing. The rate of growth, given the rising cost environment, may not match the historical rate, but it should still beat inflation. That makes this a great mix of yield and inflation protection.\nYou can fight inflation\nInflation, like most things in life, waxes and wanes over time. Right now inflation is top of mind because it is elevated, but it is something that dividend investors should always be thinking about. Growing the buying power of your dividends is a massive benefit that is far too often overlooked in a search for the biggest yields. Use today's inflation fears as a lesson that dividend growth rates stand toe to toe with yield in their importance and do a deep dive into Hormel, A. O. Smith, NextEra, and Enbridge today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":881037396,"gmtCreate":1631280951315,"gmtModify":1676530517583,"author":{"id":"4094332432138780","authorId":"4094332432138780","authorIdStr":"4094332432138780","name":"RainnieC","avatar":"https://static.tigerbbs.com/cf3aed598fd853660a3a1e9ebe364fed","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094332432138780"},"themes":[],"htmlText":"Hit the like button pls！?","listText":"Hit the like button pls！?","text":"Hit the like button pls！?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/881037396","repostId":"2166373377","repostType":4,"repost":{"id":"2166373377","pubTimestamp":1631280120,"share":"https://ttm.financial/m/news/2166373377?lang=&edition=fundamental","pubTime":"2021-09-10 21:22","market":"us","language":"en","title":"Here's Why Ziopharm Oncology Stock Is Up 18% This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2166373377","media":"Motley Fool","summary":"Recent insider stock purchases were more than a little encouraging.","content":"<h3>What happened</h3>\n<p>Shares of <b>Ziopharm Oncology</b> (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of insider stock purchases.</p>\n<h3>So what</h3>\n<p>Last Friday afternoon, just before Labor Day weekend, Ziopharm disclosed to the Securities and Exchange Commission four direct stock purchases from company insiders. James Huang, a financier of several lucrative life-science ventures including <b>Legend Biotech</b>, raised his stake from a little over 8,000 shares to around 108,000 shares. One of the company's largest shareholders, Robert Postma, bought 75,000 shares pushing his total Ziopharm holdings past 5.45 million shares.</p>\n<p><img src=\"https://static.tigerbbs.com/69f71c7423aa8bf2a971e693ce4d0936\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Kevin Boyle, who became CEO in August, wasn't <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the insiders who disclosed a big purchase on Sept. 3. That's probably because the company gave him 875,000 shares when he was appointed to the lead role on Aug. 30.</p>\n<h3>Now what</h3>\n<p>Insiders also happen to be people with bills to pay and luxuries to acquire. Investors need to remember that insider selling can mean lots of things that are mostly innocuous. Direct purchases like these, though, generally don't happen unless insiders expect the price to rise.</p>\n<p>At his former position as CEO of Kuur Therapeutics, Boyle led the company through a successful transformation that ended with a $185 million acquisition by <b>Athenex</b> this May.&nbsp;It looks like the board members who hired Boyle are confident about his ability to try Ziopharm around, too.</p>\n<p>The company's CD19-directed cellular therapy candidate started a trial in Taiwan this March, but it's on pause while the company refines its manufacturing process. With a clinical-stage pipeline collecting dust at the moment, Boyle has his work cut out for him.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ziopharm Oncology Stock Is Up 18% This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ziopharm Oncology Stock Is Up 18% This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Ziopharm Oncology (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/09/10/heres-why-ziopharm-stock-is-up-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166373377","content_text":"What happened\nShares of Ziopharm Oncology (NASDAQ:ZIOP), jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of insider stock purchases.\nSo what\nLast Friday afternoon, just before Labor Day weekend, Ziopharm disclosed to the Securities and Exchange Commission four direct stock purchases from company insiders. James Huang, a financier of several lucrative life-science ventures including Legend Biotech, raised his stake from a little over 8,000 shares to around 108,000 shares. One of the company's largest shareholders, Robert Postma, bought 75,000 shares pushing his total Ziopharm holdings past 5.45 million shares.\n\nImage source: Getty Images.\nKevin Boyle, who became CEO in August, wasn't one of the insiders who disclosed a big purchase on Sept. 3. That's probably because the company gave him 875,000 shares when he was appointed to the lead role on Aug. 30.\nNow what\nInsiders also happen to be people with bills to pay and luxuries to acquire. Investors need to remember that insider selling can mean lots of things that are mostly innocuous. Direct purchases like these, though, generally don't happen unless insiders expect the price to rise.\nAt his former position as CEO of Kuur Therapeutics, Boyle led the company through a successful transformation that ended with a $185 million acquisition by Athenex this May. It looks like the board members who hired Boyle are confident about his ability to try Ziopharm around, too.\nThe company's CD19-directed cellular therapy candidate started a trial in Taiwan this March, but it's on pause while the company refines its manufacturing process. With a clinical-stage pipeline collecting dust at the moment, Boyle has his work cut out for him.","news_type":1},"isVote":1,"tweetType":1,"viewCount":428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881033822,"gmtCreate":1631280609366,"gmtModify":1676530517427,"author":{"id":"4094332432138780","authorId":"4094332432138780","authorIdStr":"4094332432138780","name":"RainnieC","avatar":"https://static.tigerbbs.com/cf3aed598fd853660a3a1e9ebe364fed","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4094332432138780"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881033822","repostId":"2166237337","repostType":4,"repost":{"id":"2166237337","pubTimestamp":1631280187,"share":"https://ttm.financial/m/news/2166237337?lang=&edition=fundamental","pubTime":"2021-09-10 21:23","market":"us","language":"en","title":"4 of the Safest Dividend Stocks That'll Help You Crush Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=2166237337","media":"Motley Fool","summary":"Inflation is high today, but don't get scared. These four dividend stocks have handily beat inflation over the long term.","content":"<p>Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own some dividend stocks with historically high levels of dividend growth. Here are four to consider today to help you win the prolonged war against inflation.</p>\n<h3>1. We gotta eat</h3>\n<p><b>Hormel Foods</b> (NYSE:HRL) owns well-regarded, often iconic, brands like SPAM, Skippy, Planters, and Wholly Guacamole. It is fiscally conservative and focuses on innovation. The food maker is expanding overseas and reaching into new distribution segments, augmenting its already strong position in the U.S. grocery and foodservice space. There is a lot to like about this company.</p>\n<p><img src=\"https://static.tigerbbs.com/06bccf8aa0aa78d1c0a7e773d5ea3f85\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<p>The stock's 2.3% dividend yield may not be huge, but is well above the miserly 1.3% on offer from the <b>S&amp;P 500</b> index. But the real magic is that Hormel has increased its dividend annually for 55 consecutive years. The average annualized hike over the past decade was a massive 15%. That's five times the 3% historical rate of inflation growth.</p>\n<p>The best part here, however, is that this Dividend King's yield is toward the high end of its historical range. That's partly due to the impact rising inflation will have on its business in the near term (which will probably slow near-term dividend growth some), but the company's long-term history suggests it will adjust and reward investors with strong dividend growth while it does.</p>\n<h3>2. Most people like it hot</h3>\n<p><b>A. O. Smith</b> (NYSE:AOS) makes hot water heaters, which is not a particularly sexy business unless you have to take a cold shower. Then you realize why the developing world, notably China and India, are such massive growth opportunities for the company. This is not a new trend or <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's likely to be short-term in nature. Basically, A. O. Smith has a growing business in areas where an expanding middle class all want the luxury of hot water on demand. And that, as it were, is backed by a solid and stable foundation in the North American market, where replacements of older systems is the driving force. It has been a potent mix for dividend investors.</p>\n<p>Like Hormel, A. O. Smith's dividend yield, at around 1.4%, is not giant. But its dividend growth has been nothing short of incredible, at an annualized 21% over the past decade. For reference, the industrial company is a Dividend Aristocrat with 28 years' worth of dividend increases under its belt. Simply put, the buying power of A. O. Smith's dividend has grown massively over time and easily kept investors ahead of inflation. Recent dividend hikes have been less impressive, to be fair, but they continue to outpace inflation by a sizable margin.</p>\n<h3>3. Not as mundane as it seems</h3>\n<p><b>NextEra Energy</b> (NYSE:NEE) might be a bit of a shock on this list, given that utilities are generally looked at as slow, safe, and boring. And that's a great description for the company's Florida Power &amp; Light business, which is one of the largest electric utility operations in the United States. Not only is it big -- this business has long benefited from the southward migration that's been taking place in the country. The thing is, that's just half of what NextEra does. The rest of the business is being a giant provider of renewable power, a high-growth sector that has helped to fuel this utility's dividend growth for many years.</p>\n<p><img src=\"https://media.ycharts.com/charts/2ca1f5068ba536739137e72323751cae.png\" tg-width=\"720\" tg-height=\"483\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>HRL Dividend Per Share (Quarterly) data by YCharts</p>\n<p>NextEra's dividend has increased at a 10% annualized clip over the past decade, a pace management believes is sustainable over the near term. That's huge growth for a utility. And, perhaps just as interesting, this is no flash-in-the-pan company, given its 27-year string of annual dividend increases. The stock's 1.8% yield is on the low side for a utility, but if you are trying to tame inflation with dividend growth stocks, NextEra is a strong option and could add valuable diversification to your portfolio.</p>\n<h3>4. A slow transition</h3>\n<p><b>Enbridge</b> (NYSE:ENB), the last name on this list, juxtaposes against NextEra, given that its core business is operating midstream energy assets that help move oil and natural gas around the world. The big picture here is important, however, because while clean energy is definitely growing in importance, it will likely be decades before carbon fuels are expunged from the global energy pie. So Enbridge's massive, virtually irreplaceable, and largely fee-based business likely has a long future ahead of it. In fact, the company continues to invest in its midstream operations even as it has started to build out its own renewables business, so it doesn't get left behind over the long term.</p>\n<p>But what's interesting here is that Enbridge has increased its dividend at a robust 10% clip over the past decade. Oh, and the fat 6.6% dividend yield thanks to the company's energy industry ties is pretty interesting, too. The dividend, for reference, has been increased annually for 26 consecutive years. The company also has material investment plans that should keep its dividend growing. The rate of growth, given the rising cost environment, may not match the historical rate, but it should still beat inflation. That makes this a great mix of yield and inflation protection.</p>\n<h3>You can fight inflation</h3>\n<p>Inflation, like most things in life, waxes and wanes over time. Right now inflation is top of mind because it is elevated, but it is something that dividend investors should always be thinking about. Growing the buying power of your dividends is a massive benefit that is far too often overlooked in a search for the biggest yields. Use today's inflation fears as a lesson that dividend growth rates stand toe to toe with yield in their importance and do a deep dive into Hormel, A. O. Smith, NextEra, and Enbridge today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 of the Safest Dividend Stocks That'll Help You Crush Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 of the Safest Dividend Stocks That'll Help You Crush Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HRL":"荷美尔","AOS":"A.O.史密斯","NEE":"新纪元能源","ENB":"安桥"},"source_url":"https://www.fool.com/investing/2021/09/10/4-of-the-safest-dividend-stocks-thatll-help-you-cr/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166237337","content_text":"Right now inflation is spiking, so it's on everyone's mind. But it's always there, slowly eating away at the buying power of your dividends over time. The best way to deal with inflation is to own some dividend stocks with historically high levels of dividend growth. Here are four to consider today to help you win the prolonged war against inflation.\n1. We gotta eat\nHormel Foods (NYSE:HRL) owns well-regarded, often iconic, brands like SPAM, Skippy, Planters, and Wholly Guacamole. It is fiscally conservative and focuses on innovation. The food maker is expanding overseas and reaching into new distribution segments, augmenting its already strong position in the U.S. grocery and foodservice space. There is a lot to like about this company.\n\nImage source: Getty Images.\nThe stock's 2.3% dividend yield may not be huge, but is well above the miserly 1.3% on offer from the S&P 500 index. But the real magic is that Hormel has increased its dividend annually for 55 consecutive years. The average annualized hike over the past decade was a massive 15%. That's five times the 3% historical rate of inflation growth.\nThe best part here, however, is that this Dividend King's yield is toward the high end of its historical range. That's partly due to the impact rising inflation will have on its business in the near term (which will probably slow near-term dividend growth some), but the company's long-term history suggests it will adjust and reward investors with strong dividend growth while it does.\n2. Most people like it hot\nA. O. Smith (NYSE:AOS) makes hot water heaters, which is not a particularly sexy business unless you have to take a cold shower. Then you realize why the developing world, notably China and India, are such massive growth opportunities for the company. This is not a new trend or one that's likely to be short-term in nature. Basically, A. O. Smith has a growing business in areas where an expanding middle class all want the luxury of hot water on demand. And that, as it were, is backed by a solid and stable foundation in the North American market, where replacements of older systems is the driving force. It has been a potent mix for dividend investors.\nLike Hormel, A. O. Smith's dividend yield, at around 1.4%, is not giant. But its dividend growth has been nothing short of incredible, at an annualized 21% over the past decade. For reference, the industrial company is a Dividend Aristocrat with 28 years' worth of dividend increases under its belt. Simply put, the buying power of A. O. Smith's dividend has grown massively over time and easily kept investors ahead of inflation. Recent dividend hikes have been less impressive, to be fair, but they continue to outpace inflation by a sizable margin.\n3. Not as mundane as it seems\nNextEra Energy (NYSE:NEE) might be a bit of a shock on this list, given that utilities are generally looked at as slow, safe, and boring. And that's a great description for the company's Florida Power & Light business, which is one of the largest electric utility operations in the United States. Not only is it big -- this business has long benefited from the southward migration that's been taking place in the country. The thing is, that's just half of what NextEra does. The rest of the business is being a giant provider of renewable power, a high-growth sector that has helped to fuel this utility's dividend growth for many years.\n\nHRL Dividend Per Share (Quarterly) data by YCharts\nNextEra's dividend has increased at a 10% annualized clip over the past decade, a pace management believes is sustainable over the near term. That's huge growth for a utility. And, perhaps just as interesting, this is no flash-in-the-pan company, given its 27-year string of annual dividend increases. The stock's 1.8% yield is on the low side for a utility, but if you are trying to tame inflation with dividend growth stocks, NextEra is a strong option and could add valuable diversification to your portfolio.\n4. A slow transition\nEnbridge (NYSE:ENB), the last name on this list, juxtaposes against NextEra, given that its core business is operating midstream energy assets that help move oil and natural gas around the world. The big picture here is important, however, because while clean energy is definitely growing in importance, it will likely be decades before carbon fuels are expunged from the global energy pie. So Enbridge's massive, virtually irreplaceable, and largely fee-based business likely has a long future ahead of it. In fact, the company continues to invest in its midstream operations even as it has started to build out its own renewables business, so it doesn't get left behind over the long term.\nBut what's interesting here is that Enbridge has increased its dividend at a robust 10% clip over the past decade. Oh, and the fat 6.6% dividend yield thanks to the company's energy industry ties is pretty interesting, too. The dividend, for reference, has been increased annually for 26 consecutive years. The company also has material investment plans that should keep its dividend growing. The rate of growth, given the rising cost environment, may not match the historical rate, but it should still beat inflation. That makes this a great mix of yield and inflation protection.\nYou can fight inflation\nInflation, like most things in life, waxes and wanes over time. Right now inflation is top of mind because it is elevated, but it is something that dividend investors should always be thinking about. Growing the buying power of your dividends is a massive benefit that is far too often overlooked in a search for the biggest yields. Use today's inflation fears as a lesson that dividend growth rates stand toe to toe with yield in their importance and do a deep dive into Hormel, A. O. Smith, NextEra, and Enbridge today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}